Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
This article, published in the Journal of Infectious Diseases, reports on a post hoc analysis of the Phase 3 PATRICIA (PApilloma TRIal against Cancer In young Adults) trial that was performed to ascertain whether protection against low-risk human papillomavirus (HPV) types was apparent after immunization with the HPV-16/18 AS04-adjuvanted vaccine. The authors conclude that the vaccine appears to have moderate efficacy against persistent infections with a number of low-risk HPV types (HPV-6/11/74), which are responsible for the majority of external genital warts. Antibody and cell-mediated immune response to HPV-6/11 have also recently been observed.
Author: Szarewski A, Skinner SR, Garland SM, et al.
» Visit web page (English)
(Located at www.ncbi.nlm.nih.gov)
Citation: Szarewski A, Skinner SR, Garland SM, et al. Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation. Journal of Infectious Diseases. 2013;208(9):1391-1396.
Resource types: Peer-reviewed journal
Diseases/vaccines: Human papillomavirus (HPV)
Regions: North America and Europe